MMMarguerite Murray

Marguerite Murray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marguerite Murray has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony R. Braun

    University of Minnesota

    3 shared publications
  • Jonathan N. Sachs

    Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455

    3 shared publications
  • Elly E. Liao

    Department of Biomedical Engineering, College of Science and Engineering, University of Minnesota, 7-105 Nils Hasselmo Hall, 312 Church St SE, Minneapolis, Minnesota 55455, United States

    2 shared publications
  • Nagamani Vunnam

    Department of Biomedical Engineering, College of Science and Engineering, University of Minnesota, 7-105 Nils Hasselmo Hall, 312 Church St SE, Minneapolis, Minnesota 55455, United States

    2 shared publications
  • Sophia Zafari

    Department of Biomedical Engineering, College of Science and Engineering, University of Minnesota, 7-105 Nils Hasselmo Hall, 312 Church St SE, Minneapolis, Minnesota 55455, United States

    2 shared publications
  • Elly Liao

    University of Minnesota

    1 shared publication

Latest Publications

  • Multiplexed Dark FRET Biosensors: An Accessible Live-Cell Platform for Target- and Cell-Specific Monitoring of Protein–Protein Interactions in 2D and 3D Model Systems

    by Anthony R. Braun, Elly E. Liao, Nagamani Vunnam, Sophia Zafari, Noah Nathan Kochen, Marguerite Murray, Jonathan N. Sachs

    Simultaneous monitoring of multiple protein–protein interactions in live cells remains a key challenge in biology and drug discovery. While multiplexed FRET enables parallel molecular readouts, existing approaches are often constrained by spectral overlap, complex instrumentation, or incompatibility with live-cell models. To overcome these limitations and increase accessibility to the broader biological community, we present multiplexed dark FRET (MDF), a genetically encoded platform that uses spectrally distinct donors (mNeonGreen, mScarlet-I3) paired with nonemissive acceptors (ShadowY, ShadowR). We first establish that MDF fluorophores exhibit minimal background FRET under co-expression, enabling clean separation of donor lifetimes under multiplexed conditions. Using fluorescence lifetime (FLT) detection, we demonstrate MDF’s versatility through three biologically and translationally relevant examples: (1) cell-type-specific biosensing in organoids, as exemplified in 3D neuro-glial spheroids; (2) target specificity for drug discovery through discrimination of TNFR1 versus TNFR2 receptor conformations and selective FLT modulation by receptor-specific small molecules; and (3) protein misfolding, as exemplified through simultaneous monitoring of alpha-synuclein oligomerization and misfolding. We further show that MDF can be applied within a single cellular environment, demonstrating the feasibility of same-cell multiplexing under optimized transient transfection conditions. MDF provides a scalable framework for real-time, live-cell biosensing across high-throughput, target-specific, and tissue-level applications in complex biological systems.


  • Open Access

    Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery

    by Noah Nathan Kochen, Marguerite Murray, Sophia Zafari, Nagamani Vunnam, Elly E. Liao, Lihsia Chen, Anthony R. Braun, Jonathan N. Sachs

    Pathological aggregates of TDP-43 are implicated in Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. While therapeutic efforts have traditionally focused on mitigating end-stage TDP-43 aggregation, recent evidence highlights an upstream and potentially targetable event: the loss of functional nuclear TDP-43 multimers due to disrupted N-terminal domain (NTD) interactions. To address this, we developed fluorescence lifetime (FLT)-based FRET biosensors to monitor TDP-43 multimerization in living cells that couple a full-length TDP-43 FLT-FRET biosensor screen with an NTD-deletion counter screen, forming the foundation of a novel high-throughput screening (HTS) platform. Screening the 2682 compound FDA-approved Selleck library, we identified the small molecule ketoconazole, which stabilizes functional nuclear TDP-43 multimers in an NTD-dependent manner with low micromolar potency. Ketoconazole rescues TDP-43 mislocalization and aggregation, restores SREBP2 mRNA levels under TDP-43 overexpression, improves neuronal health, and partially restores motor function in a TDP-43 C. elegans model. These findings establish both the biosensors and the HTS platform as innovative tools for TDP-43 drug discovery and support an exciting translational approach for targeting TDP-43 proteinopathies.


  • Open Access

    Multiplexed Dark FRET Biosensors: An accessible live-cell platform for target- and cell-specific monitoring of protein-protein interactions in 2D and 3D model systems

    by Anthony Braun, Elly Liao, Nagamani Vunnam, Marguerite Murray, Jonathan Sachs

    Simultaneously monitoring multiple protein-protein interactions in live cells remains a key challenge in biology and drug discovery. While multiplexed FRET enables parallel molecular readouts, existing approaches are often constrained by spectral overlap, complex instrumentation, or incompatibility with live-cell models. To overcome these limitations and increase accessibility to the broader biological community, we present Multiplexed Dark FRET (MDF), a genetically encoded platform that uses spectrally distinct donors (mNeonGreen, mScarlet-I3) paired with non-emissive acceptors (ShadowY, ShadowR). Using fluorescence lifetime detection, we demonstrate MDF’s versatility through three biologically and translationally relevant examples: (1) cell-type specific biosensing in organoids, as exemplified in 3D neuro–glial spheroids; (2) target specificity for drug discovery, through discrimination of TNFR1 versus TNFR2 receptor conformations; and (3) protein misfolding, as exemplified through simultaneous monitoring of alpha-synuclein oligomerization and misfolding. MDF provides a scalable framework for real-time, live-cell biosensing across high-throughput, target-specific, and tissue-level applications in complex biological systems.